Quest Diagnostics
990 hedge funds and large institutions have $19.3B invested in Quest Diagnostics in 2025 Q2 according to their latest regulatory filings, with 119 funds opening new positions, 365 increasing their positions, 329 reducing their positions, and 82 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
45% more first-time investments, than exits
New positions opened: 119 | Existing positions closed: 82
11% more repeat investments, than reductions
Existing positions increased: 365 | Existing positions reduced: 329
10% more capital invested
Capital invested by funds: $17.5B → $19.3B (+$1.78B)
2.97% more ownership
Funds ownership: 93.27% → 96.25% (+3%)
2% more funds holding
Funds holding: 967 → 990 (+23)
33% less call options, than puts
Call options by funds: $88.3M | Put options by funds: $133M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$210M |
| 2 |
MGP
M&G plc
London,
United Kingdom
|
+$134M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
+$129M |
| 4 |
Squarepoint
New York
|
+$120M |
| 5 |
JP Morgan Chase
New York
|
+$97.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DSA
Davis Selected Advisers
Tucson,
Arizona
|
-$180M |
| 2 |
Nordea Investment Management
Stockholm,
Sweden
|
-$179M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$72.5M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$56.3M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$48.3M |
DGX Hedge Fund Activity: Q2 2025 in Review
990 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q2 2025, worth a combined $19.3B — up 10% from $17.5B a quarter earlier.
Buyers outnumbered sellers: 119 funds opened new DGX positions and 82 closed out — a net gain of 37 holders — while 365 added to existing stakes and 329 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $210M. The largest seller was Davis Selected Advisers, cutting an estimated $180M.
- 990 institutional investors held Quest Diagnostics (DGX) as of Q2 2025, up from 967 in Q1 2025.
- Funds reported $19.3B of Quest Diagnostics stock for Q2 2025, up 10% quarter-over-quarter.
- 119 funds opened new Quest Diagnostics positions in Q2 2025 and 82 closed out, a net change of +37 holders.
- The largest Quest Diagnostics buyer in Q2 2025 was T. Rowe Price Associates, an estimated $210M added.
- The largest Quest Diagnostics seller in Q2 2025 was Davis Selected Advisers, an estimated $180M sold.
Based on aggregated 13F filings for Q2 2025.